



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

21 January 2019

COMPANY UPDATE

Mobile and e-Health company G Medical Innovations Holdings Ltd (“G Medical” or “the Company”) (ASX: GMV) is pleased to provide an update on recent activities.

G Medical CEO Dr. Yacov Geva said, “We are pleased with the achievements of the Company in 2018, and the Company is well positioned for substantial growth in 2019.”

Guangzhou China, Production Facility

As previously announced (30 October 2018), the Company has now received all formal certifications from the regulatory bodies (CFDA, FDA, CE) to utilise its Guangzhou facility for production. Device production will commence in early 2019 once all final device componentry has been received for the production line. The facility will produce the Company’s Prizma and G Medical Patch (GMP) products, with the first units from the facility expected to be delivered to customers in the first quarter of 2019 to territories which have further granted regulatory approval for the specific device/s.

Yacov Geva Loan Agreement

Further to the previous announcement on 31 October 2018, the Company has now signed an agreement with Mr Geva to formalise the terms of the Loan Agreement. As previously announced, the amended unsecured Loan Amount is for up to US\$10.0m, with any amounts received up to the date of signing attracting interest of 10% per annum until the Repayment Date of April 30, 2019.

Any amounts received from the date of signing the Loan Agreement up to the Repayment Date shall attract interest at a rate of 12% per annum, with the Company committed to repaying the entire Loan Amount in cash no later than the Repayment Date, which can be extended to December 31, 2019 at the sole discretion of Mr. Geva.

Any loan amount remaining outstanding for the period May 1 to December 31, 2019, will attract interest of 15% per annum, and the Company may at its discretion repay the Loan Amount in part or in full prior to the Repayment Date. Other terms and conditions are standard for agreements of this nature.

The Board is of the view that the current terms on which Yacov Geva has agreed to provide the facilities are substantially better than those available to the Company from commercial lenders and that the Loan Agreement is otherwise on arms’ length terms.

Sales pipeline

The Company expects strong revenue growth for 2019, with revenue streams expected to come from product sales via the fulfillment of previously communication MOUs and provision of services. Revenues are also expected to increase as the Company further expands its global presence, as well as when the final outstanding regulatory approvals are granted.

IDTF & MCT Operations

The Telerhythmics acquisition (announced 2 November 2018) has increased the Company's footprint in the US vital signs medical monitoring, Independent Diagnostic Testing Facility (IDTF) and Mobile Cardiac Telemetry (MCT) markets. In addition to revenue from existing product sales, significant recurring service revenues from remote monitoring are anticipated to be generated. Furthermore, changes to Medicare rebates of remote patient monitoring (RPM) are expected to come into effect in 2019¹ and will potentially underpin a rapid growth of this revenue stream.

NASDAQ listing

The dual listing of the Company on the Nasdaq has continued to progress with the Company working with its underwriter, partners and regulators towards an anticipated listing. The Company has completed its F1 submission which has now been lodged with the US Securities and Exchange Commission for review.

HKSE Listing

As previously announced to the market, the Company is in the process of the listing of its Chinese subsidiary on the HKSE. The listing process continues to progress, with a listing anticipated within the second quarter of 2019.

Ends

Contact:

Corporate Advisors

Otsana Capital

108 Outram Street

West Perth WA 6005

Telephone: +61 8 9486 7244

www.otsana.com

Media Enquiries

Closer Communications

David Wolf

Tel: + 61 411 111 787

david@closer.com.au

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

1. SPAC -

https://spacinternational.com/pdf/CMS%20finalizes%20three%20Chronic%20Care%20Remote%20Physiologic%20Patient%20Monitoring%20codes%20that%20will%20improve%20patient%20outcomes%20and%20reduce%20cost%20--%20Sargas%20International%20_%20PRLog.pdf

About G Medical Products

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.